Linker technologies and release mechanisms for antibody–drug conjugates

References

• 1. Stack GD , Walsh JJ . Optimising the delivery of tubulin targeting agents through antibody conjugation . Pharm. Res. 29 ( 11 ), 2972 – 2984 ( 2012 ).
  Medline CASGoogle Scholar
• 2. Zolot RS , Basu S , Million RP . Antibody-drug conjugates . Nat. Rev. Drug Discov. 12 ( 4 ), 259 – 260 ( 2013 ).
  Medline CASGoogle Scholar
• 3. Senter PD . Potent antibody drug conjugates for cancer therapy . Curr. Opin. Chem. Biol. 13 ( 3 ), 235 – 244 ( 2009 ).
  Medline CASGoogle Scholar
• 4. Drachman JG , Senter PD . Antibody-drug conjugates: the chemistry behind empowering antibodies to fight cancer . Hematol. Am. Soc. Hematol. Educ. Program 2013 , 306 – 310 ( 2013 ).
  MedlineGoogle Scholar
• 5. Trail PA , Willner D , Lasch SJ et al. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates . Science 261 ( 5118 ), 212 – 215 ( 1993 ).
  Medline CASGoogle Scholar
• 6. Sapra P , Stein R , Pickett J et al. Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys . Clin. Cancer Res. 11 ( 14 ), 5257 – 5264 ( 2005 ).
  Medline CASGoogle Scholar
• 7. Sievers EL , Larson RA , Stadtmauer EA et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse . J. Clin. Oncol. 19 ( 13 ), 3244 – 3254 ( 2001 ).
  Medline CASGoogle Scholar
• 8. Linenberger ML , Hong T , Flowers D et al. Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin . Blood 98 ( 4 ), 988 – 994 ( 2001 ).
  Medline CASGoogle Scholar
• 9. Casi G , Neri D . Antibody-drug conjugates: basic concepts, examples and future perspectives . J. Control. Release 161 ( 2 ), 422 – 428 ( 2012 ).
  Medline CASGoogle Scholar
• 10. Widdison WC , Wilhelm SD , Cavanagh EE et al. Semisynthetic maytansine analogues for the targeted treatment of cancer . J. Med. Chem. 49 ( 14 ), 4392 – 4408 ( 2006 ).
  Medline CASGoogle Scholar
• 11. Ikeda H , Hideshima T , Fulciniti M et al. The monoclonal antibody nBT062 conjugated to cytotoxic maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo . Clin. Cancer Res. 15 ( 12 ), 4028 – 4037 ( 2009 ).
  Medline CASGoogle Scholar
• 12. Lutz RJ , Whiteman KR . Antibody-maytansinoid conjugates for the treatment of myeloma . MAbs 1 ( 6 ), 548 – 551 ( 2009 ).
  MedlineGoogle Scholar
• 13. Kovtun YV , Audette CA , Ye Y et al. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen . Cancer Res. 66 ( 6 ), 3214 – 3221 ( 2006 ).
  Medline CASGoogle Scholar
• 14. Kovtun YV , Goldmacher VS . Cell killing by antibody–drug conjugates . Cancer Lett. 255 ( 2 ), 232 – 240 ( 2007 ).
  Medline CASGoogle Scholar
• 15. Lopus M , Oroudjev E , Wilson L et al. Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules . Mol. Cancer Ther. 9 ( 10 ), 2689 – 2699 ( 2010 ).
  Medline CASGoogle Scholar
• 16. Erickson HK , Park PU , Widdison WC et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing . Cancer Res. 66 ( 8 ), 4426 – 4433 ( 2006 ).
  Medline CASGoogle Scholar
• 17. Ma DS , Hopf CE , Malewicz AD et al. Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen . Clin. Cancer Res. 12 ( 8 ), 2591 – 2596 ( 2006 ).
  Medline CASGoogle Scholar
• 18. Blencowe CA , Russell AT , Greco F , Hayes W , Thornthwaite DW . Self-immolative linkers in polymeric delivery systems . Polym. Chem. 2 ( 4 ), 773 – 790 ( 2011 ).
  CASGoogle Scholar
• 19. Podgorski I , Sloane BF . Cathepsin B and its role(s) in cancer progression . Biochem. Soc. Symp. ( 70 ), 263 – 276 ( 2003 ).
  MedlineGoogle Scholar
• 20. Doronina SO , Toki BE , Torgov MY et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy . Nat. Biotechnol. 21 ( 7 ), 778 – 784 ( 2003 ).
  Medline CASGoogle Scholar
• 21. Jeffrey SC , Andreyka JB , Bernhardt SX et al. Development and properties of β-glucuronide linkers for monoclonal antibody−drug conjugates . Bioconj. Chem. 17 ( 3 ), 831 – 840 ( 2006 ).
  Medline CASGoogle Scholar
• 22. Webb S . Pharma interest surges in antibody drug conjugates . Nat. Biotechnol. 29 ( 4 ), 297 – 298 ( 2011 ).
  Medline CASGoogle Scholar
• 23. Fishkin N , Maloney EK , Chari RV , Singh R . A novel pathway for maytansinoid release from thioether linked antibody-drug conjugates (ADCs) under oxidative conditions . Chem. Commun. (Camb.) 47 ( 38 ), 10752 – 10754 ( 2011 ).
  Medline CASGoogle Scholar
• 24. Perez HL , Cardarelli PM , Deshpande S et al. Antibody-drug conjugates: current status and future directions . Drug Discov. Today , ( 2013 ).
  MedlineGoogle Scholar
• 25. Kovtun YV , Audette CA , Mayo MF et al. Antibody-maytansinoid conjugates designed to bypass multidrug resistance . Cancer Res. 70 ( 6 ), 2528 – 2537 ( 2010 ).
  Medline CASGoogle Scholar
• 26. Zhao RY , Wilhelm SD , Audette C et al. Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates . J. Med. Chem. 54 ( 10 ), 3606 – 3623 ( 2011 ).
  Medline CASGoogle Scholar
• 27. Bernardes GJ , Casi G , Trussel S et al. A traceless vascular-targeting antibody-drug conjugate for cancer therapy . Angew. Chem. Int. Ed. Engl. 51 ( 4 ), 941 – 944 ( 2012 ).
  Medline CASGoogle Scholar